Wockhardt's Chicago-based subsidiary Morton Grove Pharmaceuticals has received US FDA approval for marketing an oral suspension of a combination containing 250mg/5ml of amoxicillin and 62.5mg/5ml of clavulanate potassium. This combination is used for treating several common infections, especially in children.
The details can be read here.
No comments:
Post a Comment